Pulmatrix, Inc. (PULM)
| Market Cap | 16.94M |
| Revenue (ttm) | 4.94M |
| Net Income (ttm) | -24.24M |
| Shares Out | 3.39M |
| EPS (ttm) | -8.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,165 |
| Open | 5.23 |
| Previous Close | 5.30 |
| Day's Range | 5.00 - 5.23 |
| 52-Week Range | 4.83 - 23.40 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 10.20 (+104.0%) |
| Earnings Date | May 10, 2022 |
About PULM
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchop...
Financial Performance
In 2021, Pulmatrix's revenue was $5.17 million, a decrease of -59.09% compared to the previous year's $12.63 million. Losses were -$20.17 million, 4.47% more than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for PULM stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 104.00% from the latest price.
News
Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update
Ends Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 LEXINGTON, Mass. , May 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutic...
Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update
LEXINGTON, Mass. , March 29, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non...
Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results
Pulmatrix Inc (NASDAQ: PULM) announced topline results of its recently completed Phase 1b clinical study of PUR1800 in patients with stable Chronic Obstructive Pulmonary Disease (COPD). PUR1800 is a nar...
Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD
LEXINGTON, Mass. , March 21, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-...
Pulmatrix Regains Compliance With Nasdaq Listing Requirements
LEXINGTON, Mass., March 17, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...
PULM Stock Alert: Is Pulmatrix Really Soaring More Than 1,800% Today?
As Pulmatrix executes a reverse stock split, shares of the tiny pharmaceutical company appear to be defying gravity. The post PULM Stock Alert: Is Pulmatrix Really Soaring More Than 1,800% Today?
Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline
LEXINGTON, Mass., March 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pu...
Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split
LEXINGTON, Mass. , Feb. 24, 2022 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhaled therapies to addre...
Pulmatrix Issues Letter to Stockholders
LEXINGTON, Mass., Feb. 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pul...
Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering
LEXINGTON, Mass., Dec. 17, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to addre...
Pulmatrix Announces $6.75 Million Registered Direct Offering
LEXINGTON, Mass., Dec. 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to addre...
Pulmatrix, Inc. (PULM) Reports Q3 Loss, Misses Revenue Estimates
Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of -28.57% and -56.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update
LEXINGTON, Mass., Nov. 10, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pu...
Pulmatrix Announces Resolution of Contract Dispute with Cipla
LEXINGTON, Mass., Nov. 9, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pul...
Pulmatrix, Inc. (PULM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Pulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bet on Rising P/E Investing With These Top 5 Stocks
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Pulmatrix, Inc. (PULM) Reports Q2 Loss, Tops Revenue Estimates
Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of 22.22% and 47.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update
LEXINGTON, Mass., Aug. 10, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pu...
Earnings Preview: Pulmatrix, Inc. (PULM) Q2 Earnings Expected to Decline
Pulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pulmatrix appoints Director Anand Varadan
LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-...
Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update
LEXINGTON, Mass., May 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pul...
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine
LEXINGTON, Mass., April 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...
Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio
LEXINGTON, Mass., April 12, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is re-issuing this press release solely to correct inadvertent typographical errors under the heading "Updated PUR1800 Pr...
Pulmatrix Reports 2020 Financial Results and Provides Business Update
LEXINGTON, Mass., March 23, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...